192 related articles for article (PubMed ID: 22019212)
1. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
Hoffmann MJ; Müller M; Engers R; Schulz WA
Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
9. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
Dougherty CJ; Ichim TE; Liu L; Reznik G; Min WP; Ghochikyan A; Agadjanyan MG; Reznik BN
Biochem Biophys Res Commun; 2008 May; 370(1):109-12. PubMed ID: 18355444
[TBL] [Abstract][Full Text] [Related]
10. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
[TBL] [Abstract][Full Text] [Related]
11. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
[TBL] [Abstract][Full Text] [Related]
12. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
[TBL] [Abstract][Full Text] [Related]
13. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
[TBL] [Abstract][Full Text] [Related]
14. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
17. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development.
Monk M; Hitchins M; Hawes S
Mol Hum Reprod; 2008 Jun; 14(6):347-55. PubMed ID: 18467432
[TBL] [Abstract][Full Text] [Related]
19. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]